TRACT Therapeutics
John Flavin is the current CEO of TRACT Therapeutics. John has previously served as the Chief Financial Officer of Endotronix, Inc. from May 2018 to March 2020. Prior to that, they were with Pyxis Oncology and Argonne National Laboratory. From October 2013 to March 2020, they were also a Senior Advisor at the University of Chicago.
John Flavin's educational career began with him earning a BS in finance from Marquette University. John then went on to earn an MBA in finance from Lewis University. Finally, they attended Benet Academy.
TRACT Therapeutics
TRACT Therapeutics develops a novel approach for restoring immune balance in patients receiving a solid organ transplant.